Curanex Pharmaceuticals Inc. (CURX) intrinsic value & 10-year financials
Curanex Pharmaceuticals Inc. (CURX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $4.62
- Market cap
- $117.8M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -65.6%
- Free cash flow (FY2025)
- —
CURX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$4.2M | -$0.17 | — | — | -65.6% |
| FY2024 | — | -$361.5K | -$0.01 | — | — | — |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Curanex Pharmaceuticals Inc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Curanex Pharmaceuticals Inc has historically struggled to out-earn its cost of capital, averaging just -65.6% ROIC.
Curanex Pharmaceuticals Inc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Curanex Pharmaceuticals Inc is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.